Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes
NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases
About This Grant
Type 2 Diabetes (T2D) is estimated to affect over 30 million US adults and skeletal muscle (SkM) insulin resistance (IR) is one of the primary aberrations. SkM is a complex organ comprised of different cell types including: myofibers, endothelial cells (EC), smooth muscle cells, fibro-adipogenic progenitors, satellite cells and immune cells. Effective insulin-stimulated SkM glucose uptake is dependent on 1) insulin-stimulated activation of terminal arteriole EC to perfuse microvascular units, 2) transport of substrates across capillary ECs and 3) stimulation of myofiber insulin signaling, resulting in glucose uptake. Each of these steps can be dysregulated by pro-inflammatory cytokines released from localized immune cells in the SkM niche. Therefore, different cell types in SkM can impact insulin sensitivity. Previous research has identified a dysregulated transcriptional profile with SkM IR in the basal state and during insulin stimulation. A significant limitation of these prior studies is the restriction to whole SkM homogenates and therefore not identifying which cells or spatial area within the tissue the dysregulated signals originate from. We have developed a pipeline for full-length amplification of single cells from SkM using the iCELL8 platform, resulting in 2-3 fold greater gene coverage than previous research, allowing us to investigate transcriptional aberrations that occur with SkM IR at a single cell resolution. Recent developments in spatial transcriptomics now permit transcriptional profiling on sectioned SkM tissue which identifies the location and proximity of dysregulated cells and how they relate to IR in SkM. This study will leverage a hyper-insulinemic euglycemic (HE) clamp with stable glucose isotope tracers and indirect calorimetry to assess insulin-stimulated glucose disposal (Rd) and non-oxidative glucose disposal (NOGD) in individuals with obesity with and without IR compared to an insulin sensitive control group. For the first time, the transcriptional responses to insulin in human SkM will be probed at a single cell and spatial resolution. We will identify which cells and areas of SkM respond to insulin and if they are spatially localized to each other and if their gene-network profiles correlate with a greater in vivo Rd and NOGD. This novel and innovative approach will reveal which cells (and importantly, where in SkM) the aberrations occur with SkM IR whilst dissociating the confounding effects of Obesity. Results from this proposal will identify specific molecular targets to alleviate SkM IR that will be targeted in future interventions.
Grant Summary
Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes is a NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases grant providing up to $248K for university, nonprofit, healthcare org. Applications are due 2029-02-28 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $248K
2029-02-28
- 1Confirm your organization is eligible for Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes: Frequently Asked Questions
Who is eligible for the Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes?
Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes is offered by NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes provide?
Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes provides up to $248K per award from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes deadline?
Applications for Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes are due 2029-02-28 (open). Because deadlines can change, verify the date with the funder, NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes?
To apply for Determining cell- and spatially-distinct skeletal muscle transcriptional aberrations in insulin resistance and type 2 diabetes, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases.